Retatrutide vs Semaglutide
Research Verdict
Retatrutide is the stronger research reference for the stated comparison criteria. Semaglutide: STEP-1 (14.9% weight loss), SELECT CVOT (HR 0.80, n=17,604).
Quick Answers
Which is better, Retatrutide or Semaglutide?
Retatrutide is the stronger research reference for the stated comparison criteria. Semaglutide: STEP-1 (14.9% weight loss), SELECT CVOT (HR 0.80, n=17,604).
What is the key difference between Retatrutide and Semaglutide?
Retatrutide is a triple agonist (GLP-1/GIP/glucagon) adding glucagon receptor activation to tirzepatide-like dual agonism; semaglutide is a selective GLP-1 agonist - the triple mechanism may explain the superior weight loss but introduces hepatic glycogenolysis risk.
Evidence Comparison
Semaglutide: STEP-1 (14.9% weight loss), SELECT CVOT (HR 0.80, n=17,604). Retatrutide: Phase 2 (Jastreboff 2023, NEJM) showing 24.2% mean weight loss at highest dose - potentially superior to any monoagonist. However, retatrutide lacks Phase 3 completion, CVOT data, and FDA approval. Semaglutide has the validated evidence; retatrutide has the more promising efficacy signal.
Evidence Context Favoring Retatrutide
Research contexts investigating next-generation multi-agonist obesity pharmacotherapy, accepting Phase 2-only evidence.
Evidence Context Favoring Semaglutide
Any context requiring validated Phase 3 data, CVOT evidence, or an approved agent - semaglutide is the evidence-based standard.
Side-by-Side Snapshot
| Evidence grade | Retatrutide: Level B Semaglutide: Level A |
|---|---|
| Research status | Retatrutide: Phase 3 Semaglutide: FDA Approved |
| Primary category | Retatrutide: Weight Loss & Metabolic Semaglutide: Weight Loss & Metabolic |
| Cited studies | Retatrutide: 5 Semaglutide: 6 |